Key antidepressant from AZ/Targacept fails trial

The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's ($AZN) struggling R&D operation another stinging setback and walloping Targacept ($TRGT) with a meltdown in its share value this morning. Report